ByNobleID
    OP0313 COST-EFFECTIVENESS OF A JAK1/JAK2-INHIBITOR VS. A BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUG IN A TREAT-TO-TARGET STRATEGY FOR RHEUMATOID ARTHRITIS | NobleID